Advertisement
Agios Pharmaceuticals, Inc. (AGIO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
As of 03:01PM EST. Market open.
| Previous Close | 55.08 |
| Open | 54.37 |
| Bid | 42.64 x 200 |
| Ask | 60.26 x 200 |
| Day's Range | 54.18 - 60.21 |
| 52 Week Range | 20.40 - 60.21 |
| Volume | |
| Avg. Volume | 494,092 |
| Market Cap | 3.429B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | 5.16 |
| EPS (TTM) | 11.66 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.00 |
Simply Wall St.Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News
Even though Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) posted strong earnings recently, the stock hasn't reacted in a...
GlobeNewswireAgios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGI
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.